Friday, March 31, 2023
Clinical Advances in the
Read Overview
Supported by an independent educational grant from F. Hoffmann-La Roche Ltd.
Rapid Fire
Spotlight on RET-Altered NSCLC
Rapid Fire
Perioperative Immunotherapies for NSCLC
New Challenge
New Challenge
Steering Committee Chair
Professor of Oncology
Medical Oncology Chair
Lausanne University Hospital
Lausanne, Switzerland
Steering Committee Member
Medical Oncologist
Head, Thoracic Malignancies
Vall d'Hebron University Hospital
Barcelona, Spain
Steering Committee Member
Consultant Thoracic Surgeon
Royal Brompton Hospital
Professor of Thoracic Surgery
Imperial College London
Royal Brompton Hospital
London, United Kingdom
Steering Committee Member
Associate Professor of Medicine
Director of Thoracic Oncology
Director of Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC, United States
Steering Committee Member
Head of the H12O-CNIO Lung Cancer Clinical Research Unit
Spanish National Cancer Research Centre (CNIO)
Universidad Complutense
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Madrid, Spain
Steering Committee Member
Professor of Medicine
Department of Thoracic Oncology
LungenClinic Großhansdorf
Großhansdorf, Germany
Steering Committee Chair
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Amgen; Arcus; AstraZeneca; Bayer; Beigene; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim; Bristol Myers Squibb; Clovis; Daiichi Sankyo; Debiopharm; Eli Lilly and Company; F-Star; Fishawack; Foundation Medicine; Genentech; Genzyme; Gilead; GlaxoSmithKline; Illumina; Imedex; IQVIA; Incyte; iTeos; Janssen; Merck Sharp & Dohme; Merck Serono; Merrimack; Novartis; Novocure; PER; Pfizer; PharmaMar; Phosplatin Therapeutics; Regeneron; Roche; RTP; Sanofi; Seagen Inc.; Takeda; Vaccibody
Speaker or member of speakers bureau for: AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Eli Lilly and Company; Foundation Medicine; Genentech; Illumina; Imedex; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Roche; RTP; Sanofi; Takeda
Research funding from: Amgen; AstraZeneca; Beigene; Bristol Myers Squibb; Genentech; GlaxoSmithKline; Merck Sharp & Dohme; Roche
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AbbVie; Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Daiichi Sankyo; Eli Lilly and Company; F. Hoffman La Roche; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda
Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb; Eli Lilly and Company; F. Hoffmann La Roche; Janssen; Medical Trends; Merck; Merck Sharp & Dohme; Pfizer; Sanofi; Takeda; Touch Oncology
Research funding from: Fundacion Merck Salud; Merck Healthcare KGAa
Other: Independent member of the board of Grifols
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca; Beigene; Bristol Myers Squibb; Covidien; Ethicon; Johnson and Johnson; Medela; Medtronic; Roche
Speaker or member of speakers bureau for: AstraZeneca; Bristol Myers Squibb; Covidien; Ethicon; Johnson and Johnson; Medela; Medtronic; Roche
Research funding from: Guardant Health; Medela; Medtronic
Contracted researcher for: Clearbridge Biomedics; Medela; Screencell
Patent beneficiary of: Imperial Innovations - P52435GB (Microfluidic staining), P57988GB (blood based COLD-PCR primer development)
Ownership interest: Healthcare Companion Ltd
Other: Receipt of unrestricted funds for the development of My Cancer Companion patient education app from: AstraZeneca; Bayer; Boehringer Ingelheim; Eli Lilly and Company Oncology; Takeda Oncology
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: Amgen; AstraZeneca; Bayer; Beigene; Blueprint; Boehringer Ingelheim; Bristol Myers Squibb; Catalyst; Daiichi Sankyo; Eisai; Elevation Oncology; Genentech; Gilead; Guardant Health; Janssen; Jazz Pharmaceuticals; Merck; Merck Sharp and Dohme; Novartis; Regeneron; Roche; Sanofi; Takeda; Turning Point Therapeutics
Research funding from: Alkermes; Bayer; Blueprint; Bristol Myers Squibb; Elevation Oncology; Genentech; Gilead; Merck; Merus; Nuvalent; Pfizer; RAPT; Turning Point Therapeutics
Steering Committee Member
Has the following relevant financial relationships:
Consultant or advisor for: Amgen; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Daiichi Sankyo; Eli Lilly and Company; GlaxoSmithKline; Janssen; Merck Serono; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Pharmamar; Roche; Sanofi; Takeda
Speaker or member of speakers bureau for: Amgen; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Eli Lilly and Company; Daiichi Sankyo; GlaxoSmithKline; Janssen; Merck; Merck Sharp & Dohme; Mirati; Novartis; PER; Pfizer; Pharmamar; Roche; Sanofi; Servier; Takeda
Steering Committee Member
Has no relevant financial relationships.